Articles tagged with Drug Studies
A new clinical trial from the University of Minnesota Medical School found that allopurinol did not slow kidney function in people with type 1 diabetes, despite reducing uric acid levels. The three-year study enrolled 530 participants and followed their glomerular filtration rate to assess kidney health.
A clinical trial found that reducing uric acid levels with the medication allopurinol did not slow the progression of kidney disease in people with type 1 diabetes. Despite a significant drop in uric acid levels, participants showed no improvement in their kidney function.
A large clinical trial, CKD-FIX, found that allopurinol does not prevent worsening of kidney disease. The study showed no difference in kidney function decline between the treatment and placebo groups.
The CURE Drug Repurposing Collaboratory aims to accelerate the identification of potentially effective drugs for patients with unmet treatment options. The initiative uses data collected through the FDA-NCATS CURE ID platform to identify existing drugs that demonstrate possible treatment approaches.
A recent study by SWOG Cancer Research Network found that black cancer patients are more likely to be enrolled in taxpayer-funded clinical trials compared to industry-sponsored trials. The study analyzed data from over 93,000 patients across 358 trials and found a significant disparity in representation.
A large retrospective cohort study found that flu vaccination was associated with a small increased risk for subdeltoid bursitis. Researchers suggest education and training on proper injection technique could prevent this adverse event.
Recent studies examined the association between recreational marijuana legalization and changes in traffic fatality rates. The research found a significant decrease in traffic fatalities after states legalized cannabis use.
Researchers analyzed data from over 15,000 people to find that the number of HDL particles is a more reliable predictor of heart attack and stroke risk than standard HDL cholesterol metric. In black people, neither HDL measurement was significantly associated with heart attack risk.
Researchers found that infecting patients with a safe dose of Necator americanus induces immunoregulatory responses and boosts regulatory T cells, which help control the immune system. The study showed that more than half of patients receiving the hookworm had no new lesions at all.
The Phase 1 trial demonstrated that repeated immunisation with PD01A is safe and well-tolerated, with a substantial reduction in alpha-synuclein oligomers and stable motor scores. The results suggest that PD01A may offer a promising strategy for long-term management of Parkinson's disease.
Researchers found that intensive psychosocial intervention can lead to reduced symptoms and improved functioning without antipsychotic medication in young people with early stage first episode psychosis. A larger trial is needed to investigate whether antipsychotic-free treatment could be recommended for specific groups.
A systematic review of multiple sclerosis treatments found no effective interventions for cognitive symptoms, despite over half of affected individuals experiencing cognitive dysfunction. Researchers emphasize the need for future studies focusing on cognitive outcomes and standardized criteria to inform optimal treatment choices.
A Phase II trial found that the treatment inhibited key enzyme, resulting in lowered triglyceride production and slower progression to non-alcoholic steatohepatitis. The study showed robust reduction in liver fat without corresponding increases in blood lipids.
The University of Maryland School of Medicine will partner with the Defense Advanced Research Projects Agency to rapidly test hundreds of drugs approved for other conditions to see if they can be repurposed to prevent or treat COVID-19.
Researchers investigate medication use in older adults, finding that certain hypertension medications may reduce dementia risk and improve stroke outcomes. A deprescribing program also shows promise in reducing falls risk, with primary care providers accepting over 90% of recommendations.
A recent study published in the New England Journal of Medicine found that teplizumab significantly delayed the onset of type 1 diabetes by three years compared to a placebo. The trial involved individuals at high risk of developing T1D, and those treated with teplizumab showed higher rates of insulin secretion and C-peptide levels.
The Corrona Psoriasis Registry presents studies on real-world prescribing patterns, biologic drug effects, and COVID-19 outcomes. Longitudinal studies also report improvements in quality of life and work productivity for patients treated with biologics.
A new investigator-initiated clinical trial in metastatic breast cancer is underway at HUS Comprehensive Cancer Center, testing a combination treatment regimen that targets the MYC oncoprotein. The study aims to find the right dosage for further studies and biomarkers to guide patient selection with improved precision.
Pregnant patients with COVID-19 are often excluded from drug trials due to lack of fetal safety data. A new position paper suggests using electronic health record (EHR) data to simulate drug trials, identifying safer therapeutics for treatment. This approach could offer an alternative to delivering all pregnant patients with COVID-19.
A new methodology catalogues the intestinal microbial community's effect on oral medications, identifying 57 cases of gut bacteria altering existing drugs. The framework aids in personalized treatment by predicting drug behavior and suggesting changes to therapeutic strategies.
Researchers are assessing drugs commonly prescribed to children diagnosed with COVID-19, including antiviral and anti-inflammatory medications. The study aims to understand how these drugs interact with the bodies of young patients and identify potential side effects.
Researchers developed a machine learning algorithm to predict six major clinical forms of drug-induced cardiac toxicity from gene expression data. The model demonstrated generalizability and was validated on an independent dataset, with potential applications in enhancing pharmaceutical industry safety evaluation.
A study analyzing 201 registered COVID-19 clinical trials found that many lacked key features such as control groups and blinding. The majority were also designed to enroll fewer than 100 patients, limiting their usefulness. This has raised concerns about the quality of evidence for potential treatments.
A large study in northern Italy found that even frail elderly people (65 and older) who take blood pressure medication as prescribed live longer. The healthiest older people experienced the biggest survival boost, with benefits greatest for those taking more than 75% of their prescribed doses.
The Women's Preventive Services Initiative recommends screening for anxiety in women and adolescent girls to detect specific types of anxiety and co-occurring conditions. Researchers found strong evidence that screening instruments are moderately to highly accurate.
A team of UTHSC researchers will study genetic differences in stress response, oxycodone consumption and stress-induced drug seeking in rats. The findings have great potential to translate to human conditions of opioid addiction.
A new study by Bocconi University researchers finds that the majority of phase III trial results are not significantly above threshold, contrary to previous findings. The researchers suggest that transparency and registration processes are key factors in maintaining trial integrity.
A small case series found that famotidine significantly improved symptoms of COVID-19 in patients with mild to moderate disease. The effects were felt within 24-48 hours and lasted up to 14 days. Further study is warranted to confirm the findings.
Research published in the European Heart Journal found that patients with high blood pressure are at a two-fold increased risk of dying from COVID-19 compared to those without hypertension. The study also suggests that RAAS inhibitors may be protective against COVID-19-related death.
A comprehensive study published in the Journal of Hepatology shows women and men have similar mortality rates from cirrhosis, contradicting previous research. The study analyzed data from 20,045 patients with cirrhosis, finding no difference in liver-related cause of death between genders.
Research from Aston University identifies five key burdens faced by older people and their family carers when managing medication, including ambiguity and exclusion. A new five-stage framework is proposed to help clinicians manage medication more effectively, prioritizing regular reviews involving patients and carers.
A randomized clinical trial found that hydroxychloroquine had no effect on preventing COVID-19 in healthy individuals after exposure. The trial tested 821 participants and showed a slight increase in infection rates among those taking the medication.
Researchers are investigating the use of intravenous immunoglobulin (IVIG) to treat COVID-19 patients experiencing respiratory failure. Preliminary data show promise in preventing mechanical ventilation and improving outcomes for critically ill patients.
A new study has found no link between recent cannabis use and an increased or decreased risk of ischemic stroke. Despite previous studies with conflicting results, researchers adjusted for various factors and found no association between marijuana use and stroke risk.
A recent study published in the American Journal of Pathology found that convalescent plasma therapy is a safe treatment option for patients with severe COVID-19 disease. The therapy showed significant improvement in 76% of patients, with no adverse side effects caused by the plasma transfusion.
A new Northwestern Medicine study shows that a pill taking proactively to prevent mild to life-threatening anaphylaxis could be a game-changer for those with food or drug allergies. The pill uses BTK inhibitors to block allergic reactions by inhibiting the Bruton's tyrosine kinase enzyme, which is found inside cells and mast cells.
Researchers found that rats used an unexpected strategy of adapting their behavior based on previous trial outcomes, rather than relying on a fixed optimal rule. This strategy allowed them to quickly adjust to changing environments and learn from mistakes.
A Phase 2 clinical trial has shown a novel treatment protocol to be effective in patients with intravascular large B-cell lymphoma (IVLBCL), achieving two-year survival rates of up to 76% and overall survival rates of 92%. The treatment, combining conventional drugs with high-dose methotrexate and intrathecal chemotherapy, has been fou...
A nationwide EHR study found that patients treated with phenylephrine had a lower mortality rate (24.5%) compared to dopamine and norepinephrine, even in patients with acute comorbidities. The study suggests phenylephrine as the optimal treatment for nontraumatic subarachnoid hemorrhage.
Researchers found nilotinib reduced amyloid burden and tau tangles in neurons, suggesting it may aid in Alzheimer's treatment. The study also showed improved hippocampal volume loss and reduced phospho-tau-181 levels, hinting at a potential disease-modifying effect.
A Phase II trial led by MD Anderson Cancer Center researchers found that treatment with MK-6482 resulted in a 27.9% objective response rate in patients with von Hippel-Lindau disease-associated renal cell carcinoma, with most side effects being grade 1 or 2. The drug directly targets HIF-2a and has been shown to be well-tolerated.
The gnomAD Consortium has published its first major studies of human genetic variation, revealing new insights into rare types of genetic variation. The research provides better tools for clinical geneticists to diagnose patients with rare genetic diseases and evaluate proposed drug targets.
A study from Massachusetts General Hospital found significant racial and ethnic disparities in the use of medications for opioid use disorder during pregnancy. Black and Hispanic women were less likely to receive or consistently use these medications compared to white non-Hispanic women.
A Vanderbilt University Medical Center study found that doxycycline did not reduce the growth of abdominal aortic aneurysms in patients over a two-year period. The study included 254 patients who were randomly assigned to take either doxycycline or a placebo, with no differences in aneurysm growth between the two groups.
The Ivy Brain Tumor Center is conducting a Phase 0 clinical trial to evaluate the combination of two targeted therapy drugs, abemaciclib and LY3214996, in patients with recurrent glioblastoma. The study aims to confirm that these drugs can effectively cross the blood-brain barrier and block cancer cell growth.
The study found that women and racial minorities were significantly underrepresented in pivotal trials supporting approval of new cardiometabolic medicines. This underrepresentation may lead to variation in treatment outcomes and survival, emphasizing the need for increased diversity in clinical trial participants.
A study found that no-deductible preventive drugs reduced out-of-pocket costs by $612 per year, leading to a significant increase in medication use among low-income diabetes patients. The results showed that lower-income patients benefited the most from these policies.
Researchers propose target trials to gather human drug exposure data for pregnant people, offering a basis for causal inference. Genomic data and organ-on-a-chip technologies will help validate results, making this a valid and ethical workflow for large-scale drug screening.
Researchers found that taking doxycycline had no effect on reducing the growth of abdominal aortic aneurysms over two years. The finding could lead to a change in treatment for life-threatening vascular conditions.
The study found that remdesivir reduced the median time to recovery by 4 days compared to placebo, with a survival benefit and improved clinical status. The findings support remdesivir as the standard treatment for hospitalized COVID-19 patients requiring supplemental oxygen therapy.
Researchers are testing a combination of remdesivir and baricitinib to treat severe COVID-19 cases. The trial aims to reduce inflammation caused by the virus and prevent fatal complications.
A new study from UCL-led researchers has identified the earliest brain changes due to Huntington's disease, detecting damage 24 years before clinical symptoms appear. The findings provide vital insights into the optimal time to initiate treatments, potentially delaying or preventing neurodegeneration.
A randomized clinical trial found that reducing blood pressure medications for older adults can be done safely without significant changes in short-term blood pressure control. The study included 534 adults aged 80 and older, suggesting that potential risks of continued treatment may outweigh benefits.
A large observational study found that chloroquine and hydroxychloroquine offer no therapeutic benefits for COVID-19 patients, increasing the risk of serious heart rhythm complications. The study analyzed data from nearly 15,000 patients with COVID-19 and 81,000 controls.
A study by Johns Hopkins Medicine found that women and older adults are still vastly underrepresented in lipid lowering therapy trials, despite their high disease burden. The researchers analyzed 60 studies from 1990 to 2018 and reported a modest increase in representation of women, but many trials excluded pregnant or breastfeeding wo...
Researchers found that anti-obesity medications like phentermine and topiramate can significantly reduce weight regain in patients after Roux-en-Y gastric bypass surgery. The study, which analyzed nearly 1,200 patients, showed a 10% decrease in cumulative weight regain.
A new clinical trial is testing an alpha blocker treatment to prevent severe COVID-19 symptoms by targeting the body's overactive immune response. The trial aims to lower ICU admission rates and ventilator use in patients with COVID-19, offering a secondary form of prevention until vaccines are available.
NUI Galway research shows that taking blood pressure medications can reduce the risk of developing dementia and cognitive impairment by 7%, and cognitive decline also by 7% over a four-year period. The study highlights the critical importance of controlling blood pressure in maintaining brain health, combined with a healthy lifestyle.
A study published in The BMJ found a small increased risk of musculoskeletal malformations in babies born to mothers who took fluconazole during the first trimester, but no association with oral clefts or heart defects. The risk was higher for women taking higher doses.
Researchers at MIT have identified a potential new treatment for Fragile X syndrome, a disorder causing intellectual disability and autism, using a small-molecule compound that reverses behavioral and cellular features. The compound targets the GSK3 alpha enzyme, which may also be effective against other diseases such as Alzheimer's.